Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Lyra Therapeutics (LYRA) Income from Continuing Operations (2021 - 2025)

Lyra Therapeutics has reported Income from Continuing Operations over the past 5 years, most recently at 6951000.0 for Q4 2025.

  • Quarterly results put Income from Continuing Operations at 6951000.0 for Q4 2025, up 36.69% from a year ago — trailing twelve months through Dec 2025 was 28919000.0 (up 69.05% YoY), and the annual figure for FY2025 was 28919000.0, up 69.05%.
  • Income from Continuing Operations for Q4 2025 was 6951000.0 at Lyra Therapeutics, down from 5984000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for LYRA hit a ceiling of 5984000.0 in Q3 2025 and a floor of 48131000.0 in Q2 2024.
  • Median Income from Continuing Operations over the past 5 years was 12764000.0 (2021), compared with a mean of 14190600.0.
  • Biggest five-year swings in Income from Continuing Operations: crashed 208.18% in 2024 and later skyrocketed 84.55% in 2025.
  • Lyra Therapeutics' Income from Continuing Operations stood at 13617000.0 in 2021, then decreased by 4.44% to 14222000.0 in 2022, then dropped by 6.57% to 15156000.0 in 2023, then increased by 27.56% to 10979000.0 in 2024, then skyrocketed by 36.69% to 6951000.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 6951000.0 (Q4 2025), 5984000.0 (Q3 2025), and 7437000.0 (Q2 2025) per Business Quant data.